1. Home
  2. ICUI vs MMS Comparison

ICUI vs MMS Comparison

Compare ICUI & MMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICUI
  • MMS
  • Stock Information
  • Founded
  • ICUI 1984
  • MMS 1975
  • Country
  • ICUI United States
  • MMS United States
  • Employees
  • ICUI N/A
  • MMS N/A
  • Industry
  • ICUI Medical/Dental Instruments
  • MMS Business Services
  • Sector
  • ICUI Health Care
  • MMS Consumer Discretionary
  • Exchange
  • ICUI Nasdaq
  • MMS Nasdaq
  • Market Cap
  • ICUI 3.4B
  • MMS 3.9B
  • IPO Year
  • ICUI 1992
  • MMS 1997
  • Fundamental
  • Price
  • ICUI $134.86
  • MMS $72.44
  • Analyst Decision
  • ICUI Strong Buy
  • MMS Buy
  • Analyst Count
  • ICUI 5
  • MMS 1
  • Target Price
  • ICUI $196.75
  • MMS $90.00
  • AVG Volume (30 Days)
  • ICUI 283.6K
  • MMS 468.3K
  • Earning Date
  • ICUI 05-08-2025
  • MMS 05-08-2025
  • Dividend Yield
  • ICUI N/A
  • MMS 1.66%
  • EPS Growth
  • ICUI N/A
  • MMS 31.21
  • EPS
  • ICUI N/A
  • MMS 5.00
  • Revenue
  • ICUI $2,420,093,000.00
  • MMS $5,395,260,000.00
  • Revenue This Year
  • ICUI N/A
  • MMS $1.62
  • Revenue Next Year
  • ICUI N/A
  • MMS $3.08
  • P/E Ratio
  • ICUI N/A
  • MMS $14.51
  • Revenue Growth
  • ICUI 7.22
  • MMS 5.29
  • 52 Week Low
  • ICUI $101.44
  • MMS $63.77
  • 52 Week High
  • ICUI $196.26
  • MMS $93.97
  • Technical
  • Relative Strength Index (RSI)
  • ICUI 48.47
  • MMS 51.66
  • Support Level
  • ICUI $127.91
  • MMS $71.53
  • Resistance Level
  • ICUI $135.62
  • MMS $75.19
  • Average True Range (ATR)
  • ICUI 4.35
  • MMS 1.48
  • MACD
  • ICUI -0.26
  • MMS -0.38
  • Stochastic Oscillator
  • ICUI 33.77
  • MMS 15.74

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

About MMS Maximus Inc.

Maximus Inc designs, develops, and delivers programs, enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments; U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.

Share on Social Networks: